These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The clinical pharmacology of hypotensive vasodilator drugs. Zacest R Med J Aust; 1975 Jan; 1(SP1):4-8. PubMed ID: 235713 [TBL] [Abstract][Full Text] [Related]
44. The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status. Rowell NP; Clark K Radiother Oncol; 1990 Aug; 18(4):293-8. PubMed ID: 2244017 [TBL] [Abstract][Full Text] [Related]
45. Hypotensive agents, beta-blockers, and drug-induced lupus. Hughes GR Br Med J (Clin Res Ed); 1982 May; 284(6326):1358-9. PubMed ID: 6122487 [No Abstract] [Full Text] [Related]
46. Oral hydralazine therapy for primary pulmonary hypertension. Rubin LJ; Peter RH N Engl J Med; 1980 Jan; 302(2):69-73. PubMed ID: 7350435 [TBL] [Abstract][Full Text] [Related]
47. [The propranolol-dihydralazine combination in the therapy of systemic arterial hypertension]. Ambrosioni E; Costa V; Minuzzo I; Magnani B Boll Soc Ital Cardiol; 1974; 19(2):169-73. PubMed ID: 4462800 [No Abstract] [Full Text] [Related]
48. Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension. Kuzniar J; Skret A; Piela A; Szmigiel Z; Zaczek T Obstet Gynecol; 1985 Oct; 66(4):453-8. PubMed ID: 4047535 [TBL] [Abstract][Full Text] [Related]
49. Hydralazine and beta-adrenergic blockade in the treatment of hypertension. Siitonen L; Jänne J; Keyriläinen O; Koskinen P; Leskinen O; Pitkäjärvi T; Reinikainen M Ann Clin Res; 1974 Dec; 6(6):341-6. PubMed ID: 4155933 [No Abstract] [Full Text] [Related]
50. Conversion of drug-induced SLE-syndrome by the vasodilating agent cadralazine. Mulder H Eur J Clin Pharmacol; 1990; 38(3):303. PubMed ID: 2340851 [TBL] [Abstract][Full Text] [Related]
51. Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension. Prichard BN; Thompson FO; Boakes AJ; Joekes AM Clin Sci Mol Med Suppl; 1975 Jun; 2():97s-100s. PubMed ID: 802650 [TBL] [Abstract][Full Text] [Related]
52. Acute immunologic hydralazine reaction. Clinical and serological changes after hydralazine administration to a patient with circulating antinuclear antibodies. Alarcón-Segovia D Rev Invest Clin; 1972; 24(2):167-74. PubMed ID: 4538312 [No Abstract] [Full Text] [Related]
53. Primary hypertension refractory to triple drug treatment: a study on central and peripheral hemodynamics. Andersson O; Hansson L; Sivertsson R Circulation; 1978 Oct; 58(4):615-22. PubMed ID: 688570 [No Abstract] [Full Text] [Related]
54. Lupus after six years of mild hypertension. Altus P Hosp Pract (Off Ed); 1985 Jun; 20(6):58, 60. PubMed ID: 3924927 [No Abstract] [Full Text] [Related]
55. Laryngeal manifestations of drug induced lupus. Maxwell D; Silver R J Rheumatol; 1987 Apr; 14(2):375-7. PubMed ID: 3599009 [TBL] [Abstract][Full Text] [Related]
56. Hydralazine in the management of left ventricular failure. Fitchett DH; Neto JA; Oakley CM; Goodwin JF Am J Cardiol; 1979 Aug; 44(2):303-9. PubMed ID: 463768 [No Abstract] [Full Text] [Related]
57. Drug-induced autoimmune disease. Tan EM Fed Proc; 1974 Aug; 33(8):1894-7. PubMed ID: 4135739 [No Abstract] [Full Text] [Related]
59. Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction. Nelson GI; Silke B; Forsyth DR; Verma SP; Hussain M; Taylor SH Am J Cardiol; 1983 Nov; 52(8):1036-40. PubMed ID: 6637819 [TBL] [Abstract][Full Text] [Related]